Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$19.95 - $31.0 $3.19 Million - $4.95 Million
-159,832 Reduced 93.69%
10,767 $310,000
Q3 2023

Nov 14, 2023

BUY
$21.33 - $59.42 $3.64 Million - $10.1 Million
170,599 New
170,599 $3.91 Million
Q1 2022

May 16, 2022

SELL
$36.25 - $52.02 $256,722 - $368,405
-7,082 Closed
0 $0
Q4 2021

Mar 03, 2022

BUY
$43.27 - $65.72 $306,438 - $465,429
7,082 New
7,082 $335,000
Q2 2021

Aug 16, 2021

SELL
$45.13 - $64.99 $194,961 - $280,756
-4,320 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$29.77 - $84.85 $128,606 - $366,552
4,320 New
4,320 $273,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.